Prescription-Only Apple App Helps Veterans, Active Service Members Deal With PTSD Nightmares

Comments
Loading...

NightWare, a "digital therapeutic system" that works in conjunction with Apple Inc.'s AAPL smartwatch and iPhone, is helping veterans and active service members who suffer from post-traumatic stress disorder, or PTSD, deal with nightmares and get a good night’s sleep.

What Happened: It’s available by prescription and is the first and only digital therapeutic developed specifically to treat nightmares that has received FDA approval. 

NightWare leverages information from the Apple Watch's heart rate sensor, accelerometer and gyroscope to detect a nightmare. If it senses a person having a nightmare, the platform sends haptic feedback, generating gentle pulses on the user’s wrist to cleverly disrupt the nightmare without affecting their sleep. 

See Also: How To Buy Apple (AAPL) Shares

Apple shared the story of Robert Guithues, an Army veteran who served for over two decades and has PTSD. He used to wake up at night thinking he was back in the burning oil fields outside Baghdad, but it all changed when he started using NightWare.  

“Some of the most horrific sights I’ve ever seen kept playing over and over, but when I started using NightWare, they stopped,” Guithues said. 

Why It’s Important: NightWare is prescribed to 400 patients in the U.S. so far, of which 98% are active-duty military or veterans, according to AppleInsider. 

According to a peer-reviewed "Journal of Clinical Sleep Medicine," participants who used NightWare 50% of the time had considerably better self-supported sleep than their counterparts.  

Read Next: Apple Watch User Says He Ended Up In Emergency Room After His Gadget Exploded

Overview Rating:
Good
75%
Technicals Analysis
100
0100
Financials Analysis
60
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!